INTRODUCTION

Antibiotic resistance of micro-organisms is a major challenge confronted by all scientists who are involved in antibiotic drug discovery. Bacteria widen its resistance to antibiotics by mutating existing genes (vertical evolution) or by acquiring new genes from other strains or species (horizontal gene transfer). The sharing of genes between bacteria by horizontal gene transfer occurs by many different mechanisms [1].

Methicillin-resistant *Staphylococcus aureus* (MRSA) is a nosocomial and community-acquired pathogen that has developed resistance to various antibiotics such as β-lactams, quinolones, aminoglycosides, vancomycin, oxazolidinone, and streptogramin type antibiotics [2-4]. Newly emerging community-associated MRSA (CA-MRSA) is transmissible from healthcare acquired MRSA (HA-MRSA). Some CA-MRSA strains display enhanced virulence, spreading more rapidly and causing illness much more severe than HA-MRSA infections, affecting vital organs which lead to sepsis, toxic shock syndrome, and necrotizing pneumonia [5]. One of the strategies employed to triumph over the bacterial resistance is the use of a combination of drugs. The secondary metabolites of the plants are the good sources for combination of drugs to act as multidrug resistant modifiers with varied mechanisms of action [6]. Polyphenols is a prominent class of plant metabolites possesses...
efficient antimicrobial action. A number of reports are available on the synergistic interactions of polyphenols with antibiotics to overcome microbial resistance like epigallocatechin gallate from green tea [7], tellimagrandin I and rugosin B from rose red (Rosa macdub) [8], baicalein from Scutellaria amoena [9], and corilagin from Arctostaphylos uva-ursi [10].

Rosmarinic acid (RA) is a well-known phenylpropanoid and chemically it is a dimer of caffeic acid and 3, 4-dihydroxyphenyl lactic acid, bound by an ester linkage [Figure 1]. RA belongs to the group of polyphenols. It is known for its therapeutic and cosmetic properties. It is well accounted as an antioxidant [11,12], anti-inflammatory [13,14], and antimicrobial agent [11,15,16]. RA was described to possess antimicrobial activity against wild strains of Bacillus subtilis, Micrococcus luteus and Escherichia coli [17], Pseudomonas aeruginosa, S. aureus, Shigella sp., and Enterobacter [15], Candida albicans, and Aspergillus niger [16]. Further, it was reported that RA possesses bactericidal activity against acne causing pathogens such as S. aureus, Staphylococcus epidermidis, and Propionibacterium acne through its membrane-damaging effect [18]. Previously, the synergistic effect of Rosmarinus officinalis extract with cefuroxime against MRSA was reported [19]. Although RA is stated to be an outstanding antimicrobial agent, its effect on MRSA is not yet studied in detail. Furthermore, there is nil report on the synergistic effect of RA with antibiotics against S. aureus.

Thus, the current study was designed to evaluate the antibacterial activity and to determine the minimum inhibitory concentration (MIC) of RA against S. aureus and MRSA. To develop RA as an adjuvant to antibiotics, the synergistic effect of RA with antibiotics against S. aureus and MRSA was explored. Further to understand the mechanism of action, the role of the effective synergistic combination of RA on microbial surface components recognising adhesive matrix molecules (MSCRAMM’s) – surface proteins of S. aureus and MRSA was also studied.

**MATERIALS AND METHODS**

**RA**

RA (90% pure) was obtained from Sami Labs, Bengaluru, India.

**Evaluation of Antibacterial Potency of RA**

**Agar well diffusion method**

Antibacterial activity was evaluated by agar well diffusion method according to the National Committee for Clinical Laboratory Standards [20]. Petri plates containing 20 ml Mueller-Hinton agar were seeded with 24 h culture of bacterial strains with 0.5 McFarland standard equivalent using spread plate method. The diameter wells of 6 mm were cut and 20 μl of RA was prepared using Mueller-Hinton broth as described by NCCLS, 2000 [20]. Increasing concentration of 1-10 mg/ml of RA was prepared using Mueller-Hinton broth as diluent and inoculated with 20 μl of bacterial inoculums with turbidity equivalent to 0.5 of McFarland scale. The mixture was incubated for 24 h at 37°C for the growth of bacteria. The lowest concentration at which there was no bacterial growth determined using ultraviolet spectrophotometer was taken as the MIC of RA [21].

**Bacterial Strains and Culture Medium**

S. aureus ATCC 25923 was used in the study. Clinical isolate of MRSA was obtained from Doctors Diagnostic Centre, Trichy (India), and resistance against methicillin was observed by Kirby-Bauer method. Mueller-Hinton agar (MV173) and Mueller-Hinton broth (MV391) were purchased from Hi Media Laboratories Pvt. Ltd., Mumbai, India. The bacteria were rejuvenated in Mueller-Hinton broth at 37°C for 18 h and then stocked at 4°C in Mueller-Hinton agar. Subcultures were prepared as required. The inoculum size of the bacterial culture was standardized according to the National Committee for Clinical Laboratory Standards Guideline [20]. Further, they were analyzed by Mannitol salt agar test (+), catalase test (+), fermentation and oxidation of glucose (+), DNAse test (+), and tube coagulase test (−) for the confirmation of the strain. The antibiotics amoxicillin, ofloxacin, and vancomycin were obtained from Cipla Ltd., Mumbai, India.

**Evaluation of Synergy with Antibiotics**

**Broth checkerboard method**

Broth checker board method was used to find the synergism of RA with the standard antibiotics amoxicillin, ofloxacin and vancomycin against MRSA [22]. RA was taken in the microfuge tube in ascending concentration from lowest inhibitory concentration to double the concentration of MIC and was arranged in a row. All the antibiotics were prepared in a similar manner and were arranged in a column. Using the checker board, various combinations of RA with antibiotics were obtained. The minimal concentration at which there
was no growth of organism was fixed as MIC. The fractional inhibitory concentration index (FIC index) was calculated for each combination by the formula:

$$FICA + FICB = FICI,$$

Where, $FICA = \frac{MIC of RA in combination}{MIC of RA alone}$; $FICB = \frac{MIC of any antibiotic in combination}{MIC of antibiotic alone}$. If FIC index $\leq 0.5$ – synergy; FIC index $>0.5$ to $<1$ - additive; FIC index $>1$ to $<4$ - no interaction; FIC index $>4$ – antagonism.

**Time Kill Analysis**

Time-kill kinetics was analyzed only for synergistic combinations of antibiotics and RA confirmed by checker board method [23]. Mueller-Hinton broth with combinations was inoculated with organism which was adjusted to 0.5 McFarlands standards and kept in a shaking incubator at 35°C. Samples were taken at 0, 6, 12, 24 and 30 h after inoculation. The extent of growth inhibition was analyzed at standardized OD$_{620}$ nm.

**Effect of RA on Surface Protein Fraction**

Mueller-Hinton broth was inoculated with the overnight bacterial culture of *S. aureus*, MRSA, and RA. The mixture was then incubated and centrifuged to form pellet. The pellet was resuspended in 1 M LiCl in about one-tenth of the media volume. The suspension was then incubated in a shaker at 42°C for 2 h. The bacteria were pelleted and the supernatant containing noncovalently attached surface proteins to the plasma membrane was removed. The proteins were quantified by recording the absorbance at 280 nm. 1 M LiCl was used as blank. The protein fraction was then run on sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-PAGE) and compared with the standard proteins [24].

**RESULTS**

**Antibacterial Activity**

The antibacterial activity of RA against *S. aureus* and MRSA was evaluated by agar well diffusion method by measuring the inhibition zones. RA showed inhibition zone with 12.4 mm diameter against *S. aureus* and 11.6 mm against MRSA. Inhibition zone for RA and antibiotics were compared and shown in Table 1. MIC of RA was evaluated by broth dilution method and shown in Table 2. MIC of RA was found to be 0.8 mg/ml against *S. aureus* and 10 mg/ml against MRSA.

**Synergistic Evaluation of RA and Antibiotics**

To improve the antibiotic efficiency as well as to reduce the antibiotic dose, the antibacterial activity of the combinations of RA and standard antibiotics (amoxicillin, ofloxacin, and vancomycin) on susceptibility of *S. aureus* and MRSA by broth checker board method was investigated. The calculated FIC index is shown in Table 2. RA at $\frac{1}{4}$ × MIC value reduced the MIC of vancomycin, amoxicillin, and ofloxacin by $\frac{1}{4}$ times against *S. aureus*. However against MRSA, only vancomycin was found to be synergistic. All the synergistic combinations have shown FIC index value of 0.5. As MIC value for amoxicillin and ofloxacin was not observed against MRSA until the dose level of 80 $\mu$g/ml, further determinations for its MIC was not carried out and thus these two antibiotics were not studied for synergism by broth checker board method.

**Time-Kill Kinetic Assay**

The effect of RA, antibiotics, and synergic combinations were studied on the bacterial growth rate by time-kill kinetic

| Compounds | Diameter of inhibition zones (mm) against *S. aureus* | Concentration (volume – 20 $\mu$l) | Diameter of inhibition zones (mm) against MRSA | Concentration (volume – 20 $\mu$l) |
|-----------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| RA        | 12.4±0.4                         | 0.2 mg/ml                       | 11.6±0.4                         | 2 mg/ml                         |
|           | 15.4±0.5                         | 0.4 mg/ml                       | 14.2±0.2                         | 4 mg/ml                         |
|           | 16.4±0.4                         | 0.6 mg/ml                       | 17.6±0.2                         | 6 mg/ml                         |
|           | 18.4±0.6                         | 0.8 mg/ml                       | 20.0±0.4                         | 8 mg/ml                         |
| Streptomycin | 27±0.1                           | 10 $\mu$g/disc                  | 9.0±0.2                          | 10 $\mu$g/disc                  |
| Ofloxacin | 14±0.4                           | 5 $\mu$g/disc                   | -                               | 5 $\mu$g/disc                   |
| Ciprofloxacin | 22±0.2                            | 5 $\mu$g/disc                  | 7.0±0.3                          | 5 $\mu$g/disc                   |
| Chloramphenicol | 28±0.2                          | 30 $\mu$g/disc                   | 20±0.5                           | 30 $\mu$g/disc                   |

*S. aureus*: Staphylococcus aureus, MRSA: Methicillin-resistant Staphylococcus aureus, RA: Rosmarinic acid

| Strains                | Antibiotics                  | MIC of antibiotics (mg/ml) | MIC of RA (mg/ml) | FIC index | Interpretation |
|------------------------|-----------------------------|----------------------------|-------------------|-----------|----------------|
| *S. aureus* (ATCC 25923) | Vancomycin                  | 20                         | 0.8               | 0.5       | Synergy        |
|                        | Ofloxacin                   | 20                         | 0.5               | 0.5       | Synergy        |
|                        | Amoxicillin                 | 30                         | 0.5               | 0.5       | Synergy        |
| MRSA (Clinical isolate) | Vancomycin                  | 40                         | 10                | 0.5       | Synergy        |
|                        | Ofloxacin                   | $>80$                      | -                 | -         | -              |
|                        | Amoxicillin                 | $>80$                      | -                 | -         | -              |

*S. aureus*: Staphylococcus aureus, MRSA: Methicillin-resistant Staphylococcus aureus, RA: Rosmarinic acid, MIC: Minimum inhibitory concentration
Ekambaram, et al.: Synergy between rosmarinic acid and antibiotics

J Intercult Ethnopharmacol ● 2016 ● Vol 5 ● Issue 4

assay. The results are shown in Figures 2-5. It was observed that the synergistic combinations of RA and antibiotics have shown better time kill kinetics as compared to RA and antibiotics alone against S. aureus. The synergistic combinations retained a strong effect on decreasing bacterial growth in lag phase, log phase, and stationary phase when compared with individual amoxicillin and RA as shown in Figure 2. Amoxicillin and RA alone showed stronger effect only on the stationary phase and a lower effect in lag phase of S. aureus. The synergistic combination of RA + ofloxacin showed a much better inhibition in the log and stationary phase compared to RA and ofloxacin individually as shown in Figure 3. RA + vancomycin combination showed a better effect than individual compounds on log phase, while in lag and stationary phase showed effects similar to singular drugs as shown in Figure 4. Similarly, on synergistic combinations against MRSA, there was marked inhibition in lag and stationary phase on comparing with vancomycin and RA individually as shown in Figure 5. The antibacterial effects of all synergistic combinations were much potent in log phase compared to the individual effects.

Effect of RA on Surface Protein Fraction of MRSA

MSCRAMMs were isolated by protein precipitation method from S. aureus and MRSA and were then studied by running the protein fractions on SDS-PAGE. The gel picture [Figure 6] showed expression of proteins from 40 to 90 kDa in S. aureus control. A single band was expressed in the RA as well as vancomycin-treated sample, whereas the RA + vancomycin combination treated sample showed no protein expression. No bands were observed. Similarly, the protein expression in MRSA control showed intense bands, which were appeared to be suppressed in vancomycin and RA alone treated samples [Lane 2 and Lane 3 in Figure 7]. The RA + vancomycin combination have shown marked reduction in number and intensity of bands when compared to control lane.

DISCUSSION

RA, a polyphenol found in higher concentration in R. officinalis is a well-known therapeutic and cosmetic secondary metabolite
penetration capability into the bacterial cell wall. Further, as the MIC of RA against MRSA (10 mg/ml) was found to be higher in concentration, an effort was taken to study the synergistic possibilities of RA with antibiotics to develop RA as an adjuvant to the antibiotics. The results proved that RA was synergistic with the commercial antibiotics amoxicillin, ofloxacin and vancomycin against S. aureus and only with vancomycin against MRSA. The synergistic effect of RA was further confirmed by time-kill study, where the combinations have shown marked reduction of bacterial growth over time especially in the log phase of bacterial growth when compared with the individual antibiotics and RA against both S. aureus as well as MRSA. These results clearly show that RA combined with antibiotics could produce maximum bactericidal effect may be because of its higher efficacy in the log phase of bacterial growth. RA at the specified MIC was found to be synergistic with the antibiotics. There are several virulence factors in the surface membrane proteins of bacteria. MSCRAMMs are a major virulence factor, which is present on the cell surface. They are covalently anchored transmembrane molecules in bacteria and have been shown to be a prominent antimicrobial target for antibiotics. MSCRAMMs are the major factors to cause infections as they mediate the initial host-bacterial interactions. It includes clumping factor A, protein A and fibronectin binding protein A, which are the major factor for initiating host-pathogen interactions [35,36]. Apart from MSCRAMMs cell surface proteins also contains penicillin-binding protein 2a and fmt B gene encoded protein, which is the major cause for resistance in MRSA. To study the possible mechanism of action of RA, the effect of RA on surface proteins was explored. The expression of MSCRAMM’s in S. aureus was comparatively lesser in respect of MRSA, as resistant strains (MRSA) express a large number of surface proteins as its virulence factors. The combination of RA and vancomycin could able to suppress the expression of surface proteins (MSCRAMM’s) completely in S. aureus, whereas its effect on MRSA was only moderate as the combination showed minimum number of intense bands when compared with its control. The results clearly indicate that the antibacterial activity of RA might be due to its action on the surface proteins MSCRAMM’s of S. aureus and MRSA.

CONCLUSION

To conclude, RA is an antibacterial agent against S. aureus and MRSA, but the MIC values are on the higher side. Even then, RA may act as an adjuvant or resistant modulating agent confirmed by its synergistic effect with antibiotics. The suppression of surface proteins MSCRAMM’s by RA in S. aureus and MRSA might be one of the mechanism responsible for its antibacterial action. However, future studies on increasing the efficacy of RA and identification of the detailed mechanism for its synergism with antibiotics has to be studied.

ACKNOWLEDGMENTS

The authors gratefully acknowledge Sami Labs, Bengaluru (India) for providing RA as generous gift sample for the study.
We also acknowledge TEQIP Phase II grant, Anna University BIT campus, Tiruchirappalli for funding the project.

REFERENCES

1. Levy SB. The challenge of antibiotic resistance. Sci Am 1988;278:32-9.
2. Projan SJ. Antibiotic resistance in the Staphylococci. In: Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Rood JD, editors. Gram-Positive Pathogens. Washington, DC: American Society for Microbiology; 2000. p. 463-70.
3. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348:1342-7.
4. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wenersten C, Venkataraman L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358:207-8.
5. Raygada JL, Levine DP. Managing CA-MRSA infections: Current and emerging options. Infect Med 2009;26:49-58.
6. Hemaishvaya S, Kruthiventki A, Doble M. Synergism between natural products and antibiotics against infectious diseases. Phytomedicine 2008;15:639-52.
7. Zhao WH, Hu QZ, Hara Y, Shimamura T. Inhibition of pinocillinase by epigallocatechin gallate resulting in restoration of antibacterial activity of pinocillinase producing Staphylococcus aureus. Antimicrob Agents Chemother 2002;46:2266-8.
8. Shiota S, Shimizu M, Mizusima T, Ito H, Hatanot Y, Yoshida T, et al. Restoration of effectiveness of beta-lactams on methicillin-resistant Staphylococcus aureus by tellimagrandin I from rose red. FEMS Microbiol Lett 2000;185:135-8.
9. Liu IX, Durham DG, Richards RM. Baicalin synergy with beta-lactam antibiotics against methicillin resistant Staphylococcus aureus and other beta-lactam resistant strain of S. aureus. J Pharm Pharmacol 2000;52:361-6.
10. Shiota S, Shimizu M, Sugiyama J, Morita Y, Mizushima T, Tsuchiya T. Mechanisms of action of corilagin and tellimagrandin I that remarkably potentiate the activity of beta-lactams against methicillin-resistant Staphylococcus aureus. Microbiol Immunol 2004;48:67-73.
11. Moreno S, Scheyer T, Romano CS, Vojnov AA. Antimicrobial and antimicrobial activities of rosemary extracts linked to their polyphenol composition. Free Radic Res 2006;40:223-31.
12. She GM, Xu C, Liu B, Shi RB. Polyphenolic acids from mint (the aerial parts of Mentha haplocalyx Briq.) with DPPH radical scavenging activity. Free Radic Res 2006;40:223-31.
13. Kuhnt M, Pröbstle A, Rimpler H, Bauer R, Heinrich M. Biological Evaluation of Auricularia auricula-judae as a possible source of new antimicrobial agents. J Med Food 2008;11:1015-22.
14. Lee SY, Miyamoto YJ, McIntyre BW, Hohk M, McCrea KW, McDevitt D, et al. The Staphylococcus aureus map protein is an immunomodulator that interferes with T cell-mediated responses. J Clin Invest 2002;110:1461-71.
15. Abedini A, Roumy V, Mahieux S, Biabiany et al. Rosmarinic acid and its methyl ester as antimicrobial components of the hydroethanolic extract of Hylotis attorbens Poit. (Lamiaceae). Evid Based Complement Alternat Med 2013;2013:604536.
16. Zampini IC, Arias ME, Cudmani N, Ordoñez RM, Isla, Maria I, Moreno S. Antibacterial potential of non volatile constituents of Rosmarinus officinalis against 37 clinical isolates of multidrug resistant bacteria. Bol Latinoam Plant Med Aromatocos 2013;12:201-8.
17. Klancnik C, Možina SS, Zhang Q. Anti-CAMPYLOBACTER activities and resistance mechanisms of natural phenolic compounds in CAMPYLOBACTER. PLoS One 2012;7:e51800.
18. Benedec D, Hangandu T, Onigla I, Tiperuciuc B, Olah NK, Raita O, et al. Assessment of rosmarinic acid content in six Lamiaceae species extracts and their antioxidant and antimicrobial potential. Pak J Pharm Sci 2015;28 6 Suppl:2297-303.
19. Jordán MJ, Lax V, Rota MC, Lorán S, Sotomayor JA. Relevance of carnosic acid, carnosol, and rosmarinic acid concentrations in the in vitro antioxidant and antimicrobial activities of Rosmarinus officinalis (L.) melhanic extracts. J Agric Food Chem 2012;60:9603-8.
20. Budhiraja A, Dhingra G. Development and characterization of a novel antiacne niosomal gel of rosmarinic acid. Drug Deliv 2015;22:723-30.
21. Stanojkovic T, Kolundzic B, Cirić A, Sokovic M, Nikolic D, Kundakovica T. Cytotoxicity and antimicrobial activity of Satureja kitaibelli wierz. Ex heuff (lamiaceae). Dig J Nanomater Biostruct 2013;8:845-54.
22. Slobodniková L, Filásová S, Hupková H, Grancai D. Rosmarinic acid interaction with planktonic and biofilm Staphylococcus aureus. Nat Prod Commun 2013;8:1747-50.
23. Sacco C, Bellumori M, Santomuro F, Donato R, Capei R, Innocenti M, et al. An in vitro evaluation of the antibacterial activity of the non-volatile phenolic fraction from rosemary leaves. Nat Prod Res 2015;29:1537-44.
24. Shahidi F, Nasiri M. Nutritional and Pharmacological Effects of Food Phenolics. Phenolics in Food and Nutraceuticals. New York: CRC Press; 2004. p. 331-402.
25. Goodyear CS, Silverman GJ. Death by a B cell superantigen: In vivo VH-targeted apoptotic suprabclonal B cell deletion by a Staphylococcal toxin. J Exp Med 2003;197:1125-39.
26. Muthukrishnan G, Quinn GA, Lamers RP, Díaz C, Cole AL, Chen S, et al. Exoproteome of Staphylococcus aureus reveals putative determinants of nasal carriage. J Proteome Res 2011;10:2064-78.

© SAGEYA. This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, noncommercial use, distribution and reproduction in any medium, provided the work is properly cited.

Source of Support: Nil, Conflict of Interest: None declared.